Notice from the acting CEO – SAHPRA
Cannabidiol (CBD) is one of the naturally occurring non-psychoactive cannabinoids
found in the Cannabis plant (including Cannabis sativa L.).
Prior to 23 May 2019, CBD was classified in terms of the Medicines and Related
Substances Act 101 of 1995 (Medicines Act), as either Schedule 4 (when intended
for therapeutic use), or Schedule 7 (when not for therapeutic use).
Medicines and substances which fall into Schedule 4 are only available on a
doctor’s prescription, while those classified in Schedule 7 are not readily available to
members of the general public.
On the recommendation of SAHPRA, the Minister removed CBD from Schedule 7,
classifying all CBD containing products as Schedule 4 substances.
(See the Government Notice No: R755. Government Gazette No: 42477).
Find the rest of the press release attached